PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Escitalopram

Drugs in development · updated 30 October 2026

Escitalopram: clinical trials and development status

Other names and codes: Lexapro

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Escitalopram is in 11 active clinical trials (recruiting or ongoing, phases I–III) for 15 diseases. The most advanced phase is III.

11Active trials
IIIMost advanced phase
15Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Escitalopram and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Bipolar disorderIII2NCT05603104
Alzheimer's diseaseIII1NCT03108846
ConstipationII–III1NCT05519683
DementiaIII1NCT03108846
Irritable bowel syndromeII–III1NCT05519683
Major depressive disorderIII1NCT05603104
Psychomotor agitationIII1NCT03108846
SchizophreniaIII1NCT05603104
AltruismI–II1NCT06696482
AphasiaII1NCT03843463
AsthmaII1NCT06216535
Autism spectrum disorderII1NCT06826326
GliomaII1NCT03728673
StrokeII1NCT03843463
Well-beingEarly I1NCT06796946

Everything on Escitalopram

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch